National Comprehensive Cancer Network
- Educational Events & Programs
- NCCN Annual Conference: Clinical Practice Guidelines & Quality Cancer Care™
- NCCN Annual Congress: Hematologic Malignancies™
- Regional Guidelines in Oncology Symposia
- NCCN Guidelines Update Webinar Series™
- State-of-the-Art Approaches to the Treatment of NSCLC
- NCCN Academy for Excellence & Leadership in Oncology™
- NCCN Resource Tool: REMS
- NCCN CME/CE Programs
- NCCN Oncology Case Management Program™
- NCCN International Programs
NCCN Oncology Research Program (ORP)
NCCN ORP Recent News
NCCN ORP Investigator Steering Committee
NCCN ORP Testimonials
NCCN ORP for Industry
NCCN Research & Business Resources
Everolimus added to National Comprehensive Cancer Network (NCCN) Kidney Cancer Guidelines as subsequent therapy following failure of tyrosine kinase inhibitor therapy (TKI)
On Monday, April 13, 2009, everolimus was added to the NCCN Clinical Practice Guidelines in Oncology™ for Kidney Cancer as a category 1 option for relapsed or unresectable stage IV disease in patients with predominant clear cell histology who have progressed on prior TKI therapy.
View the complete updated version of the NCCN Kidney Cancer Guidelines
View the accompanying press release.
E-mail
Print
Mark
|
|
|
|
|
|
|
||